Geovani Faddoul

Geovani Faddoul

Auto-generated profile, based on publicly available information

Geovani Faddoul

Department of Medicine, Albany Medical College, NY, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Kidney360
Verified
Journal Article
Open access
LSLoay Salman
Loay Salman
LMLaisel Martinez
Laisel Martinez
GFGeovani Faddoul
Geovani Faddoul
CMChristina Manning
Christina Manning
KAKarim Ali
Karim Ali
RVRoberto Vazquez-Padron
Roberto Vazquez-Padron
Diabetic kidney disease (DKD) is the leading cause of CKD and ESKD in the United States and worldwide. Pharmacotherapy and lifestyle modifications for glycemia, dyslipidemia, and BP control have shown success in slowing the progression of DKD. Traditional treatments, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and more recently the use of sodium-glucose cotransporter 2 inhibitors, nonsteroidal selective mineralocorticoid receptor antagonists, such as finerenone, and glucagon-like peptide 1 receptor agonists, have led to added benefits on various outcomes. However, significant residual risk for DKD progression remains despite the current standard-of-care approaches. Arteriolar hyalinosis (AH) is among the key findings seen on kidney biopsies of patients with DKD. It results from the excessive accumulation of hyaluronan (HA) in the arterioles. AH has not been targeted specifically by any of the therapeutic methods currently being used. We discuss in this manuscript the potential use of a selective therapy targeting AH and the increased total renal HA deposits using a HA synthesis inhibitor in DKD.


21 December 2023 in Clinical Transplantation
Verified
Journal Article
Closed access
EAEmmanuel Albert Aydin‐Ghormoz
Emmanuel Albert Aydin‐Ghormoz
JPJason Perlmutter
Jason Perlmutter
NKNaoru Koizumi
Naoru Koizumi
JOJorge Ortiz
Jorge Ortiz
GFGeovani Faddoul
Geovani Faddoul

8 March 2026 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
JLJordan Loon
Jordan Loon
MLMeng-Hao Li
Meng-Hao Li
SMSwati Mehta
Swati Mehta
JOJorge Ortiz
Jorge Ortiz
MMMauricio Monrroy
Mauricio Monrroy
GFGiovanni Faddoul
Giovanni Faddoul

15 May 2026 in Clinical Transplantation
Verified
Journal Article
Closed access
HCHannah Cohen
Hannah Cohen
DTDeric Toro
Deric Toro
DZDayanna Zuluaga
Dayanna Zuluaga
GFGiovanni Faddoul
Giovanni Faddoul
SRSid D Ray
Sid D Ray
SKSohai Khan
Sohai Khan

2 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
KAKunle Apanisile
Kunle Apanisile
MLMeng-Hao Li
Meng-Hao Li
GFGiovanni Faddoul
Giovanni Faddoul
OEObi Ekwenna
Obi Ekwenna
NKNaoru Koizumi
Naoru Koizumi
Kidney transplant recipients experience a higher burden of several malignancies, yet the factors associated with prostate cancer presentation after transplantation remain poorly understood. Unlike malignancies strongly associated with impaired immune surveillance, prostate cancer has not consistently demonstrated an increased incidence after transplantation, suggesting that different mechanisms may underlie disease presentation. This study evaluated recipient, donor, transplant, immunologic, and immunosuppressive factors associated with prostate cancer phenotype after kidney transplantation. A retrospective cohort study was conducted using national transplant registry data from adult kidney transplant recipients diagnosed with post-transplant prostate cancer between 2015 and 2024. Cases were classified as de novo (no pre-transplant history of prostate cancer) or recurrent (documented pre-transplant history). Multivariable Firth penalized logistic regression was used to evaluate factors associated with recurrent phenotype. Prespecified sensitivity analyses included deceased donor restricted models, incorporation of donor organ quality variables, and adjustment for time from transplantation to cancer diagnosis. Exploratory machine learning analyses included elastic net logistic regression, random forest, and extreme gradient boosting. The cohort included 660 recipients, of whom 623 (94.4%) had de novo disease and 37 (5.6%) had recurrent disease. Recipient age was the only variable consistently associated with recurrent phenotype across primary and sensitivity analyses (adjusted odds ratio per year 1.11, 95% CI 1.05–1.17; p<0.001). Immunosuppressive regimen, donor characteristics, immunologic variables, and time from transplantation to cancer diagnosis were not independently associated with phenotype in the primary cohort. In deceased donor restricted analyses, alemtuzumab induction showed an exploratory association with recurrent phenotype, although estimates were imprecise. Machine learning models demonstrated modest discrimination and calibration and did not outperform penalized regression approaches. These findings suggest that, among kidney transplant recipients with prostate cancer, differences between recurrent and de novo presentation are more closely associated with recipient age and underlying disease characteristics than with transplant exposures or specific immunosuppressive regimens.